LIPIGON PHARMACEUTICALS AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.31 SEK | +11.51% |
|
+19.23% | -28.07% |
Strengths
- Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- Low profitability weakens the company.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
Ratings chart - Surperformance
Sector: Pharmaceuticals
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -28.07% | 3.74M | - | ||
| +56.89% | 823B | C+ | ||
| +39.52% | 627B | B | ||
| -6.55% | 353B | C+ | ||
| +15.99% | 320B | B- | ||
| +7.92% | 295B | C+ | ||
| +13.74% | 239B | B+ | ||
| +13.83% | 220B | B- | ||
| -0.49% | 219B | A+ | ||
| +7.94% | 167B | C+ |
Investor Rating
Trading Rating
-
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
-
EV / Sales
Price to Book
-
Price to Free Cash Flow
-
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
-
4 months EPS revision
-
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
- Stock Market
- Equities
- LPGO Stock
- Ratings Lipigon Pharmaceuticals AB
